Skip to main content About News Giving All Departments Contact Us Site Map
 University of Texas Southwestern Medical School
 
Search       
Print Friendly  
spacer Home Education Research Patient Care Faculty & Administration Resource Careers

Clinical Trials :: Feeling Down, Sad, Blue or Depressed?



Ad Title: Feeling Down, Sad, Blue or Depressed?
Study Title: Treatment Prediction in Adolescent and Adult Depression--Clone Created
Protocol Number: 032004-047
Department(s) involved in the Study: Pediatrics, Psychiatry
Purpose of the Study: This investigation seeks to understand the mechanism(s) underlying the developmental differences, such as exposure to light, patterns of sleep, neuroendocrine activity and antidepressant (AD) response, in adolescent and adult depression. In addition, the study aims to identify those patients, both youngsters and adults, who might benefit from AD treatment in general, and from bupropion treatment in particular.
Participant Eligibility: Subjects will be between 12 years and 0 months and 50 years and 11 months, inclusive (12-21 years in the adolescent group; 25-50 years for adults). All subjects will be able to speak and read English in order to discuss and report about health, symptoms, and possible side-effects effectively with the staff and attending psychiatrist. Participants should weigh at least 90 lbs, and sexually active females must use a reliable birth control method (e.g., oral contraceptives, condom and jelly). All subjects will meet DSM-IV criteria for current Major Depressive Disorder and/or Dysthymia at the time of intake, and will continue to meet these criteria until the start of the treatment phase.
Disease/Condition Under Study: Depression
Cancer Related Study: No
Study Drug(s): bupropion
Study Device(s):
Study Doctor: Dr. Uma Rao
Location of Study:
Sites Recruiting at this Site
Children's Medical Center Yes
Contact Phone: 214-648-5250
Email: TeenHealth@utsouthwestern.edu
Other Information: This study will consist of three phases: 1) a screening phase; 2) actigraphy and laboratory (two 2-night sessions, one week apart) sleep assessment (a total of 14 days for both in-home and lab assessments); 3) a treatment phase with sustained-release bupropion lasting 8 weeks; 4) a six-month follow-up interview assessment.
Website Keywords: Mental Health, Psychiatry
Medical Keywords: treatment prevention